Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential

被引:225
作者
Wong, Piu
Iwasaki, Masayuki
Somervaille, Tim C. P.
So, Chai Wai Eric
Cleary, Michael L. [1 ]
机构
[1] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA
[2] Inst Canc Res, Haemato Oncol Sect, Sutton SM2 5NG, Surrey, England
关键词
leukemia stem cells; MLL; meis1; pbx; TALE homeodomain proteins;
D O I
10.1101/gad.1602107
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Oncogenic mutations of the MLL histone methyltransferase confer an unusual ability to transform non-self-renewing myeloid progenitors into leukemia stem cells (LSCs) by mechanisms that remain poorly defined. Misregulation of Hox genes is likely to be critical for LSC induction and maintenance but alone it does not recapitulate the phenotype and biology of MLL leukemias, which are clinically heterogeneous presumably reflecting differences in LSC biology and/or frequency. TALE ( three-amino-acid loop extension) class homeodomain proteins of the Pbx and Meis families are also misexpressed in this context, and we thus employed knockout, knockdown, and dominant-negative genetic techniques to investigate the requirements and contributions of these factors in MLL oncoprotein-induced acute myeloid leukemia. Our studies show that induction and maintenance of MLL transformation requires Meis1 and is codependent on the redundant contributions of Pbx2 and Pbx3. Meis1 in particular serves a major role in establishing LSC potential, and determines LSC frequency by quantitatively regulating the extent of self-renewal, differentiation arrest, and cycling, as well as the rate of in vivo LSC generation from myeloid progenitors. Thus, TALE proteins are critical downstream effectors within an essential homeoprotein network that serves a rate-limiting regulatory role in MLL leukemogenesis.
引用
收藏
页码:2762 / 2774
页数:13
相关论文
共 60 条
[1]   Hox regulation of normal and leukemic hematopoietic stem cells [J].
Abramovich, Carolina ;
Humphries, R. Keith .
CURRENT OPINION IN HEMATOLOGY, 2005, 12 (03) :210-216
[2]   Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9 [J].
Ayton, PM ;
Cleary, ML .
GENES & DEVELOPMENT, 2003, 17 (18) :2298-2307
[3]   Functional and regulatory interactions between Hox and extradenticle genes [J].
Azpiazu, N ;
Morata, G .
GENES & DEVELOPMENT, 1998, 12 (02) :261-273
[4]   Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: Potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia [J].
Calvo, KR ;
Knoepfler, PS ;
Sykes, DB ;
Pasillas, MP ;
Kamps, MP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (23) :13120-13125
[5]   Pbx1/Pbx2 requirement for distal limb patterning is mediated by the hierarchical control of Hox gene spatial distribution and Shh expression [J].
Capellini, Terence D. ;
Di Giacomo, Giuseppina ;
Salsi, Valentina ;
Brendolan, Andrea ;
Ferretti, Elisabetta ;
Srivastava, Deepak ;
Zappavigna, Vincenzo ;
Selleri, Licia .
DEVELOPMENT, 2006, 133 (11) :2263-2273
[6]   Interaction of MLL amino terminal sequences with menin is required for transformation [J].
Caslini, Corrado ;
Yang, Zhaohai ;
El-Osta, Mohamad ;
Milne, Thomas A. ;
Slany, Robeft K. ;
Hess, Jay L. .
CANCER RESEARCH, 2007, 67 (15) :7275-7283
[7]   PBX PROTEINS DISPLAY HEXAPEPTIDE-DEPENDENT COOPERATIVE DNA-BINDING WITH A SUBSET OF HOX PROTEINS [J].
CHANG, CP ;
SHEN, WF ;
ROZENFELD, S ;
LAWRENCE, HJ ;
LARGMAN, C ;
CLEARY, ML .
GENES & DEVELOPMENT, 1995, 9 (06) :663-674
[8]  
Dibner C, 2001, DEVELOPMENT, V128, P3415
[9]   The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10 [J].
DiMartino, JF ;
Ayton, PM ;
Chen, EH ;
Naftzger, CC ;
Young, BD ;
Cleary, ML .
BLOOD, 2002, 99 (10) :3780-3785
[10]   The Hox cofactor and proto-oncogene Pbx1 is required for maintenance of definitive hematopoiesis in the fetal liver [J].
DiMartino, JF ;
Selleri, L ;
Traver, D ;
Firpo, MT ;
Rhee, J ;
Warnke, R ;
O'Gorman, S ;
Weissman, IL ;
Cleary, ML .
BLOOD, 2001, 98 (03) :618-626